I think it’s going to get approved

Discussion in 'BiogenIdec' started by anonymous, May 3, 2021 at 8:19 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    If it gets approved there will be a lot of monitoring. If pet scans not covered pets won’t pay it will cost too much. I was excited but no longer many doctors have their concerns.. this drug I once thought was good but now I’m concerned with what the true efficacy. Too much spinning the data and other drugs like this have failed. Need to start looking..what happened to biogen it’s not the same company.
     

  2. anonymous

    anonymous Guest

    Duh
     
  3. anonymous

    anonymous Guest

    Lots of drugs have been approved with unimpressive clinical efficacy data. Throw in bad safety data as well. This is no rarity so for anyone long in the chin and wanting Biogen to fail, you better wake up.
     
  4. anonymous

    anonymous Guest

    Most don’t want or think it should be approved, are hesitant to use if it is because of the serious side effects and believe it’s worth a fraction of the predicted price. That doesn’t sound like a recipe for success.
     
  5. anonymous

    anonymous Guest

    Serious adverse Aria was only 1.5% of all patients enrolled in both trials. That is peanuts, and while obviously requires monitoring to ensure this patient doesn't fall into that 1.5%, definitely overblown to think that Aria side effects are a limiting factor.
    On efficacy trial showed ~20% improvement vs placebo in the positive trial, and in the negative trial same efficacy shown if patients got 8 or more infusions.
    Ask yourself if your mother or father had Alzheimer's would you want to try for a 20% improvement or prefer to do nothing? Is 1.5% risk of serious Aria going to make you think twice or would you be comfortable with periodic MRI to monitor?
    In the absence of any other option besides enrolling into a clinical trial, seems like an easy decison for families with loved ones.
    Will the FDA think the same?
     
  6. anonymous

    anonymous Guest

    This is precisely why you did not get hired. This will require true sales people who know how to sell in a restrictive access environment. No sample droppers or caters. Again, that’s why you did not get hired.
     
  7. anonymous

    anonymous Guest

    Why are you on CP talking about clinical results for a non-approved product. Shut the fuck up. PLEASE!
     
  8. anonymous

    anonymous Guest

    So you're saying 20% chance that aducanumab offers a benefit compared to doing nothing along with a 1.5% risk of serious adverse event? Seems like greater than 10-to-1 benefit to risk profile, I would take those odds in Vegas.
     
  9. anonymous

    anonymous Guest

    Agreed. Soooooo many lame pharma reps who have never had to sell anything before.
     
  10. anonymous

    anonymous Guest

    And with ADU surely being denied in the next month or so, they will continue not selling anything - besides themselves in interviews looking for a new job
     
  11. anonymous

    anonymous Guest

    Omg so clever. I see what you did there.
     
  12. anonymous

    anonymous Guest

    again, you can’t sell period and it’s why you cry on here.
     
  13. anonymous

    anonymous Guest

    Never. Getting. Approved.
     
  14. anonymous

    anonymous Guest

    Post of the century.

    Our HR department has cautioned us against Adu reps.
     
  15. anonymous

    anonymous Guest

    Dude you’re a leaky ass cushion.
     
  16. anonymous

    anonymous Guest


    Ooff....that’s a tough sell.
     
  17. anonymous

    anonymous Guest

    OMG save it. Such trash. The experts have basically stated it simply just means they possibly will last a bit longer in a long term care facility and nothing more. It may extend their unfortunate demise by a few months if lucky. So save your nauseating over the top message. You are only offering FALSE hope to so many and actually not amounting to really anything.
     
  18. anonymous

    anonymous Guest

    What? To sell something with very weak data that actually doesn't help patients and feel good about it?
     
  19. anonymous

    anonymous Guest

    Ok here’s to the 1-2 dolts who have wasted the past 6 months of their lives going off on Biogen on this site about Adu.

    You zoom see on June 7 that this product will launch. Make no mistake, Adu is the most important launch in the history of Biogen. The company has deep pockets tontje time of 600 million to see this product will launch. Adu will be met with a very high demand from both neuro’s. and caregivers. Adu offers something that no other treatment options offer. That is it will reduce the cognitive decline cusses by the disease. There are over 600 specialists ready to use Adu.

    I know those same 1-2 dolts we hate on this post but Biogen has the deep pockets to pull this off especially with so much riding on it. Sit back and enjoy your last few weeks of being wrong.
     
  20. anonymous

    anonymous Guest

    LOL thanks for the laugh idiot. 1-2 people? You've got to be crazy. Yes, we will "zoom" see. It doesn't matter how much of a deep pocket Biogen has, it isn't going to be approved you moron.